Needham Maintains Buy on Biogen, Lowers Price Target to $305
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Ami Fadia maintains a 'Buy' rating on Biogen (NASDAQ:BIIB) but has lowered the price target from $323 to $305.

August 08, 2023 | 9:33 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Biogen's price target has been lowered from $323 to $305 by Needham, though the 'Buy' rating is maintained.
The lowering of the price target by Needham could potentially create a negative sentiment among investors. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the stock. This could lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100